|
|
 |
 |
|
|
|
| |
|
|
 |
|
January 23, 2012
Pharmalucence begins operations at our new Corporate HeadQuarters in Billerica Massachusetts. While manufacturing operations and personnel remain in Bedford MA while our new facility project continues, all administrative staff has now relocated to 29 Dunham Road, Billerica, MA 01821. Our toll free number remains 1-800-221-7554, but some employee direct dial numbers have changed.
December 27, 2011
Pharmalucence Supplemental New Drug Application (sNDA) for the use of Sulfur Colloid Injection (SCI) in the localization of lymph nodes in melanoma patients has been accepted for review by FDA.
July 29, 2011
Pharmalucence partners with Robert Bosch Packaging Technology, Inc. to supply State-of-the-Art Isolated Filling Equipment for its new Drug Production Facility in Billerica, MA. PDF
July 25, 2011
Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) in the localization of lymph nodes in breast cancer patients. PDF
July 7, 2011
Pharmalucence partners with Integrated Project Services (IPS) for Design and Construction of State-of-the-Art Pharmaceutical Production Facility in Billerca MA. pdf
March 2, 2011
Pharmalucence to cease manufacturing of Pulmolite® (Kit for the Preparation of Technetium Tc99m Albumin Aggregated for Injection). Click here for details: PDF
August 23, 2010
Pharmalucence Mebrofenin amended labeling approved by FDA, post-reconstitution expiry extended to 18 hours. Click here to view new Mebrofenin product summary sheet and package insert: PDF
June 3, 2010
Pharmalucence Announces Purchase of New Property in Billerica MA, to be Developed into New Corporate Headquarters and State-of-the-Art Drug
Manufacturing Facility, beginning Summer 2010.
|
|
|
|
| |
| |
|
|
| Pharmalucence, Inc.
Is a leading provider of radiopharmaceuticals, including a broad range of Technetium Tc 99m cold kits.
The company has recently received FDA approval to manufacture and market their Kit for the Preparation of Technetium Tc 99m Sestamibi Injection, a generic version of the industry's leading myocardial perfusion agent. Pharmalucence also provides contract and private label formulation development and manufacturing services of human injectables in either liquid or lyophilized form.
|
|
 |
|
|
|
|
|
|
|
|
|
| |
|
|
|
